SPOTLIGHT: Merck KGaA blueprints new plant

Germany's Merck KGaA is investing €190 million into a new biopharmaceutical production plant in Darmstadt, the second largest such investment the company has ever made. The plant will make Erbitux, Merck's top-selling drug. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.